Research programme: phosphodiesterase IV inhibitors - Memory Pharmaceuticals
Alternative Names: MEM-1018; MEM-1091; MEM-1917; PDE4 inhibitors - Memory; R 1627Latest Information Update: 29 Mar 2010
At a glance
- Originator Memory Pharmaceuticals
- Developer Memory Pharmaceuticals; Roche
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Major depressive disorder
Most Recent Events
- 29 Mar 2010 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
- 20 Mar 2008 Discontinued - Preclinical for Depression in USA (PO)
- 14 Mar 2008 Preclinical development is ongoing